ArticleBMC medical imaging2025
Consensus clustering based on CT radiomics has potential for risk stratification of patients with clinical T1 stage lung adenocarcinoma.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Radiomics-Based Prediction of Treatment Response in Non-Small Cell Lung Cancer Using Pre-Treatment CT Imaging Features.Diagnostics (Basel, Switzerland) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to clinically risk-classify patients with clinical stage T1 LUAD based on consensus clustering of CT radiomics to help clinics provide personalized treatment strategies for patients with early stage LUAD. MATERIALS: Clinical, pathological and CT imaging data of patients who underwent surgical resection and pathologically confirmed lung adenocarcinoma from September 2018 to May 2021 were retrospectively analysed. The clinical and pathological information included age, gender, smoking history, tumor location, pathological subtype, infiltration level, lymph node metastasis (LNM), visceral pleural infiltration (VPI), lymphovascular invasion (LVI), spread through air space (STAS), Ki-67 proliferation index, and gene mutation information. Unsupervised consensus clustering analysis was performed based on the radiomic features of CT images to determine the optimal cluster values and evaluate the effect of consensus clustering. Patients were grouped according to the consensus clustering results, and compared with the histopathological characteristics of the tumors, genomic information and subgroup analyses were performed in invasive adenocarcinomas and sub-solid lesions.
resultsTotally 497 cases were determined to be classified into 2 clusters (optimal), with 258 (51.9%) cases in cluster 1 and 239 (48.1%) cases in cluster 2. There were statistically significant differences between cluster 1 and cluster 2 in micropapillary component, solid component, STAS, and Ki-67 proliferation index (p < 0.001), as well as statistically significant differences in LNM and VPI (p = 0.031 and 0.012 respectively). Additionally, micropapillary component, solid component, STAS, and Ki-67 proliferation index were also statistically different in subgroup analyses of invasive adenocarcinomas and sub-solid foci (p < 0.05). The clusters 1 and 2 were statistically different only in HER2 mutations (p < 0.001).
conclusionConsensus clustering based on CT radiomics can identify the associations of radiomic features between pathological risk factors and genomic features in clinical stage T1 lung adenocarcinoma, which can help clinical risk stratification of stage T1 lung adenocarcinoma patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.